US equities
|
NVDA
$240.20
▲+0.54%
SPCX
$173.21
▲+1.24%
MU
$1,064.66
▲+0.07%
MRVL
$289.51
▲+6.73%
AMD
$654.31
▲+3.57%
INTC
$115.00
▼-1.02%
AVGO
$379.28
▲+4.63%
TSLA
$380.42
▲+0.45%
NVDA
$240.20
▲+0.54%
SPCX
$173.21
▲+1.24%
MU
$1,064.66
▲+0.07%
MRVL
$289.51
▲+6.73%
AMD
$654.31
▲+3.57%
INTC
$115.00
▼-1.02%
AVGO
$379.28
▲+4.63%
TSLA
$380.42
▲+0.45%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.995
+0.225 (+8.12%)
Delayed Quote
Updated: 2:09 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
7 A-Rated Biotech Stocks Worth Betting on in June
↗
June 14, 2024
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.
Via
InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
June 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
June 05, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
June 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
June 05, 2024
Via
ACCESSWIRE
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 04, 2024
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!
Via
InvestorPlace
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
June 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 30, 2024
Via
Benzinga
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 23, 2024
Via
ACCESSWIRE
7 A-Rated Penny Stocks Work Betting On in H2 2024
↗
May 30, 2024
For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.
Via
InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
May 28, 2024
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
May 28, 2024
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy
May 22, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
May 21, 2024
Via
ACCESSWIRE
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study
May 17, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
May 17, 2024
Via
ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets
May 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation
May 14, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation
May 14, 2024
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance
May 09, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Set to Extend Operational Runway to 2025 Following Warrant Exercise and Issuance
May 09, 2024
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2
May 08, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing of Human Pilot Study No. 2, GLP-1-H24-2
May 08, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 08, 2024
Via
ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
May 07, 2024
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology
May 07, 2024
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
Investor Brand Network
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches New Research Program to Evaluate DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
